Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline

AI Briefing

• – Bayer to acquire Perfuse Therapeutics to complement ophthalmology pipeline.
• – Bayer to gain full rights to PER-001, a Phase II clinical development candidate for Glaucoma and Diabetic Retinopathy.
• – Deal expands Bayer's presence in therapeutic areas with high unmet medical need.